Juniper Pharmaceuticals (NASDAQ:JNP) had its price target boosted by Roth Capital from $12.00 to $24.00 in a report released on Friday. The brokerage currently has a buy rating on the specialty pharmaceutical company’s stock.
Separately, ValuEngine upgraded Juniper Pharmaceuticals from a sell rating to a hold rating in a research note on Friday. Two investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Juniper Pharmaceuticals currently has a consensus rating of Buy and an average target price of $29.00.
Shares of Juniper Pharmaceuticals (NASDAQ:JNP) opened at $10.90 on Friday. Juniper Pharmaceuticals has a 12-month low of $3.65 and a 12-month high of $11.15. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.00 and a quick ratio of 1.68. The firm has a market capitalization of $118.20, a P/E ratio of 18.17 and a beta of 0.58.
Several hedge funds and other institutional investors have recently modified their holdings of JNP. Goldman Sachs Group Inc. raised its stake in shares of Juniper Pharmaceuticals by 3.4% in the second quarter. Goldman Sachs Group Inc. now owns 21,735 shares of the specialty pharmaceutical company’s stock valued at $110,000 after purchasing an additional 715 shares in the last quarter. Macquarie Group Ltd. acquired a new position in shares of Juniper Pharmaceuticals in the third quarter valued at $129,000. Deutsche Bank AG raised its stake in shares of Juniper Pharmaceuticals by 112.1% in the fourth quarter. Deutsche Bank AG now owns 37,181 shares of the specialty pharmaceutical company’s stock valued at $180,000 after purchasing an additional 19,653 shares in the last quarter. Bailard Inc. acquired a new position in shares of Juniper Pharmaceuticals in the fourth quarter valued at $267,000. Finally, Nationwide Fund Advisors raised its stake in shares of Juniper Pharmaceuticals by 5,500.0% in the second quarter. Nationwide Fund Advisors now owns 56,000 shares of the specialty pharmaceutical company’s stock valued at $283,000 after purchasing an additional 55,000 shares in the last quarter. Institutional investors and hedge funds own 39.67% of the company’s stock.
WARNING: “Roth Capital Raises Juniper Pharmaceuticals (JNP) Price Target to $24.00” was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://sportsperspectives.com/2018/03/13/roth-capital-raises-juniper-pharmaceuticals-jnp-price-target-to-24-00.html.
About Juniper Pharmaceuticals
Juniper Pharmaceuticals, Inc is a women’s health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized product.
Receive News & Ratings for Juniper Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juniper Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.